- Home
- JHI vs UNCY Comparison
JHI vs UNCY Comparison
Compare JHI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHI | UNCY |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 100.6M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JHI | UNCY |
|---|---|---|
| Price | $12.14 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.40 |
| AVG Volume (30 Days) | 34.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10,044.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.73 | $3.33 |
| 52 Week High | $14.26 | $8.74 |
Technical Indicators
Market Signals| Indicator | JHI | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 46.57 |
| Support Level | $11.73 | $3.34 |
| Resistance Level | $13.49 | $4.18 |
| Average True Range (ATR) | 0.14 | 0.24 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 65.09 | 60.38 |
Price Performance
Historical ComparisonAbout JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others. The company's portfolio includes Corporate Bonds, Term Loans, U.S Government Agency, and Others.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.